MISSISSAUGA, ON, July 26, 2021 /PRNewswire/ - Nuvo Pharmaceuticals
Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or
the Company), a Canadian focused, healthcare company with global
reach and a diversified portfolio of commercial products, today
announced it expects to release its second quarter 2021 financial
results before markets open on Monday,
August 9, 2021.
The Company will subsequently hold a conference call the same
day, Monday, August 9, 2021 at
11:00 a.m. ET, hosted by Jesse Ledger, Miravo's President & Chief
Executive Officer and other senior management. A
question-and-answer session will follow the corporate update.
CONFERENCE CALL DETAILS
DATE: Monday, August 9, 2021
TIME: 11:00 a.m. ET
DIAL-IN NUMBER: 416 764 8688 or 1 888 390 0546
TAPED REPLAY: 416 764 8677 or 1 888 390 0541 / REPLAY
PASSCODE: 457561#
The audio webcast can be accessed at:
https://produceredition.webcasts.com/starthere.jsp?ei=1470704&tp_key=267126102f
An archived replay of the webcast will be available by clicking
the link above.
About Miravo Healthcare
Miravo is a Canadian focused,
healthcare company with global reach and a diversified portfolio of
commercial products. The Company targets several therapeutic
areas, including pain, allergy, neurology and dermatology.
The Company's strategy is to in-license and acquire
growth-oriented, complementary products for Canadian and
international markets. Miravo's head office is located in
Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the Company's
manufacturing facility is located in Varennes, Québec, Canada. The
Varennes facility operates in a
Good Manufacturing Practices (GMP) environment respecting the U.S,
Canada and E.U. GMP regulations
and is regularly inspected by Health Canada and the U.S. Food and
Drug Administration. For additional information, please visit
www.miravohealthcare.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/miravo-healthcare-announces-second-quarter-2021-results-release-date-and-conference-call-details-301340668.html
SOURCE Nuvo Pharmaceuticals Inc.